Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/E ratio is N/A as of 2026-10-06T19:47:51.028Z.
Calculation as of: 2026-10-06T19:47:51.028Z.
Quote observation: 2026-10-06T19:45:12.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: a2c27257439ebc7e0324c407d6ec5b5d27bfaa5dcb56832ff3962ee146363265
PE RATIO
N/A
Market Cap
$106.16M
PE Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$106.90M
PE Ratio
N/A
TTM Avg
2144.18
3Y Avg
993.27
5Y Avg
551.35
Market Cap
$104.18M
PE Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$103.72M
PE Ratio
N/A
TTM Avg
17.69
3Y Avg
17.69
5Y Avg
17.69
| NAME | MARKET CAP | PE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Immunic, Inc. (IMUX) | $106.11M | N/A | N/A | N/A | N/A |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP)vs › | $106.16M | N/A | N/A | N/A | N/A |
| Cumberland Pharmaceuticals Inc. (CPIX)vs › | $106.90M | N/A | 2144.18 | 993.27 | 551.35 |
| Outlook Therapeutics, Inc. (OTLK)vs › | $107.41M | N/A | N/A | N/A | N/A |
| Definitive Healthcare Corp. (DH)vs › | $104.21M | N/A | N/A | N/A | N/A |
| Apyx Medical Corporation (APYX)vs › | $107.59M | N/A | 3.95 | 3.95 | 3.95 |
| Polaryx Therapeutics, Inc. Common Stock (PLYX)vs › | $104.18M | N/A | N/A | N/A | N/A |
| Vivani Medical, Inc. (VANI)vs › | $108.23M | N/A | N/A | N/A | N/A |
| Black Diamond Therapeutics, Inc. (BDTX)vs › | $103.72M | N/A | 17.69 | 17.69 | 17.69 |
| Aardvark Therapeutics, Inc. Common Stock (AARD)vs › | $108.87M | N/A | N/A | N/A | N/A |
Trailing P/E
N/A
Forward P/E
N/A
Forward P/E is calculated using analyst consensus EPS estimates for the current or next fiscal year.
Calculation:
Current Price
$7.79
Forward EPS (Est.)
$-3.57
Forward P/E
N/A
Source: FMP Analyst Consensus Estimates. Forward EPS represents the average analyst estimate for the nearest fiscal year.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
